Erratum to "Updates on pathogen inactivation of plasma using Theraflex methylene blue system" [Transfus. Apher. Sci. 38(3) (2008) 271-280] (DOI:10.1016/j.transci.2008.04.004);Updates on pathogen inactivation of plasma using Theraflex methylene blue system

Transfusion and Apheresis Science

Volumn 38, Issue 3, 2008, Pages 271-280

  Seghatchian, Jerard ^a   Walker, Wolfram H ^b   Reichenberg, Stefan ^b  

^a Blood Components/Apheresis Technology and Haemostasis/Thrombosis Consultancy   (United Kingdom)

^b MacoPharma International GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMA PROTEIN;

ARTICLE; CYTOMEGALOVIRUS INFECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; PHOTODYNAMICS; PROCESSING; STORAGE; TRYPANOSOMA CRUZI; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS;

EID: 44949224338     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2009.03.001     Document Type: Erratum

References (46)

1. Allain J.P., Bianco C., Blajchman M.A., Brecher M.E., Busch M., Leiby D., et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 19 (2005) 110-126
2. Lambrecht B., Mohr H., Knüver-Hopf J., and Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60 (1991) 207-213
3. Verpoort T., Chollet S., Lebrun F., Goudaliez F., Mohr H., and Walker W.H. Elimination of methylene blue from photodynamically treated virus inactivated fresh-frozen plasma: the Blueflex filter. Transfus Clin Biol 8 (2001) 103S
4. Boppp K.F., Morell A., Indrak K., Parkkinen J., Mertens H., Mohr H., et al. Pathogen inactivation of labile blood products. Transfus Med 11 (2001) 149-175
5. Wagner S.J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 16 (2002) 61-66
6. Wainwright M., Mohr H., and Walker W.H. Phenothiazinium derivatives for pathogen inactivation in blood products. J Photochem Photobiol 86 (2007) 45-58
7. Bachmann B., Knuver-Hopf J., Lambrecht B., and Mohr H. Target structures for HIV-1 inactivation by methylene blue and light. J Med Virol 47 (1995) 172-178
8. Mohr H., Lambrecht B., and Selz A. Photodynamic virus inactivation of blood components. Immunol Invest 24 (1995) 73-85
9. Mohr H., Knuver-Hopf J., Gravemann U., Redecker-Klein A., and Mueller T.H. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 44 (2004) 886-890
10. Knuver-Hopf J., Vogt I., and Mohr H. The influence of photodynamic treatment on the genome and the infectivity of Parvovirus B19. Transfus Clin Biol 8 Suppl. 1 (2001) P141
11. Girones N., Bueno J.L., Carrion J., Fresno M., and Castro E. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 91 (2006) 285-291
12. O'Shaughnessy D.F., Atterbury C., Bolton M.P., Murphy M., Thomas D., Yates S., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126 (2004) 11-28
13. Achour A. Phenothiazines and prion diseases: a potential mechanism of action towards oxidative stress. Int J Antimicrob Agents 20 4 (2002) 305-306
14. Amaral L., and Kristiansen J.E. Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants. Int J Antimicrob Agents 18 5 (2001) 411-417
15. Specific Specifications for Blood Components in Guidelines for the Blood Transfusion Services in the United Kingdom. 7th edition, 2007. Published by TSO. Access on-line: .
16. Pohler P., Walker W.H., Reichenberg S., Mohr H., Gravemann U., and Müller T.H. Methylene blue treated plasma: pharmacokinetic and toxicological profile of MB and photoproducts. Vox Sang 87 Suppl. 3 (2004) 119
17. Little AD. National Toxicology Program. In: Little AD, editor. Executive summary of safety and toxicity information: methylene blue. Cambridge, MA; 1990.
18. Hejtmancik M.R., Ryan M.J., Toft J.D., Persing R.L., Kurtz P.J., and Chhabra R.S. Hematological effects in F344 rats and B6C3F1 mice during the 13-week gavage toxicity study of methylene blue trihydrate. Toxicol Sci 65 (2002) 126-134
19. Mohr H., Knuver-Hopf J., Lambrecht B., Scheidecker H., and Schmitt H. No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Hematol 65 (1992) 224-228
20. Aznar J.A., Molina R., and Montoro J.M. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 39 (1999) 748-750
21. Hornsey V.S., Drummond O., Young D., Docherty A., and Prowse C.V. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 11 1 (2001) 31-36
22. Seghatchian J., and Krailadsiri P. What's happening? The quality of methylene blue treated FFP and cryo. Transfus Apher Sci 25 (2001) 227-231
23. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion 43 (2003) 1322-1329
24. Politis C., Kavallierou L., Hantziara S., Katsea P., Triantaphylou V., Richardson C., et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 92 (2007) 319-326
25. Cardigan R., Garwood M., and Hornsey V. Effect of freeze-thawing, leucocyte depletion, methylene blue (MB) treatment and removal on teh quality of FFP. Vox Sang 83 (2002) 190
26. Depasse F., Sensebe L., Seghatchian J., Andreu G., and Samama M.M. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfus Apher Sci 33 1 (2005) 63-69
27. Gravemann U, Kusch M, Koenig H, Mohr H, Mueller TH. Thrombin generation capacity of methylene blue/light - treated plasma. Abstract ISBT 2008.
28. Castrillo A., Eiras A., Cid J., Castro A., Adelantado M., Abalo M., et al. Quality of methylene blue plasma over the last five years. Vox Sang 91 Suppl. 3 (2006) 182
29. Reichenberg S., Gravemann U., Pohler P., and Walker W.H. Characteristics of Macopharma Theraflex MB-Plasma. Vox Sang 93 Suppl. 1 (2007) 169P312
30. Guide to the preparation, use and quality assurance of blood components. 13th edition. Council of Europe; 2007.
31. Garwood M., Cardigan R.A., Drummond O., Hornsey V.S., Turner C.P., Young D., et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 43 (2003) 1238-1247
32. Hornsey V.S., Young D.A., Docherty A., Hughes W., and Prowse C.V. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Transfus Med 14 (2004) 369-374
33. Seghatchian M.J., Mackie I.J., and Hirst K. A tentative mechanism of prepeak formation in cryoprecipitate. Thromb Res 31 2 (1983) 391-396
34. Seghatchian J. Regulatory control, standardisation and characterisation of clinical concentrates. In: Seghatchian J., and Savidge J. (Eds). Factor VIII - von Willibrand factor (1989), CRC Press, Boca Raton (FL) 223-253
35. Larrea L., Calabuig M., Soler M.A., Solves P., Mirabet V., and Roig R. Our nine years experience in plasma inactivation. Vox Sang 93 Suppl. 1 (2007) 167
36. Atance R., Pereira A., and Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41 (2001) 1548-1552
37. Solheim B.G., Cid J., and Osselaer J.C. Pathogen reduction technologies. In: Lozano M., Contreras M., and Blajchman M. (Eds). Global perspective in transfusion medicine (2006), AABB Press, Bethesda (MD)
38. Fontana S., Kremer Hovinga J.A., Laemmie B., and Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 90 (2006) 245-254
39. de la Rubia J., Arriaga F., Linares D., Larrea L., Carpio N., Marty M.L., et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 114 3 (2001) 721-723
40. Alvarez-Larran A., Del Rio J., Ramirez C., Albo C., Pena F., Campos A., et al. Methylene blue-photoinactivated plasma vs fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86 (2004) 246-251
41. Del Rio-Garma J., Alvarez-Larran A., Martinez C., de la R.J., Zamora C., Muncunill J., et al. Methylene blue photoactivated plasma (MBPIP) vs fresh frozen plasma (FFP) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP): a multicentric prospective-cohort study. Vox Sang 93 Suppl. 1 (2007) 41
42. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., and Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 (2004) 39-44
43. Cardigan R., Allford S., and Williamson L. Levels of Von Willebrand Factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol 117 (2002) 253-254
44. Gravemann U., Behague M., Reichenberg S., Mohr H., Walker W.H., Verpoort T., et al. Evaluation of a novel illumination device for the treatment of MB-plasma. Vox Sang 93 Suppl. 1 (2007) 165
45. Seghatchian J. What is happening? Are the current acceptance criteria for therapeutic plasma adequate?. Transfus Apher Sci 31 (2004) 67-73
46. Kumar V., Pinkoski L., Corash L., and Chapman J. Preparation of fibrin sealant using methylene blue treated plasma using the Cryoseal FS-System. Vox Sang 93 Suppl. 1 (2007) 54-274